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http://www.biomedcentral.com/1471-2407/14/293RESEARCH ARTICLE Open AccessA novel oxygen carrier “YQ23” suppresses the
liver tumor metastasis by decreasing circulating
endothelial progenitor cells and regulatory T cells
Chang Xian Li1, Bing L Wong2, Chang Chun Ling1, Yuen Yuen Ma1, Yan Shao1, Wei Geng1, Xiang Qi1,
Sze Hang Lau2, Sui Yi Kwok2, Na Wei2, Fei Chuen Tzang2, Kevin TP Ng1, Xiao Bing Liu1, Chung Mau Lo1
and Kwan Man1*Abstract
Background: Surgical therapies are the first-line treatments for hepatocellular carcinoma (HCC) patients. However,
the high incidence of tumor metastasis after liver surgery remains a severe problem. We aim to investigate the roles
and the underlying mechanism of YQ23, stabilized non-polymeric diaspirin cross-linked tetrameric hemoglobin, in
liver tumor metastasis after major hepatectomy and partial hepatic ischemia reperfusion (I/R) injury.
Methods: An orthotopic liver tumor model in Buffalo rat was established using the hepatocellular carcinoma cell
line McA-RH7777. Major hepatectomy for tumor-bearing lobe and partial hepatic I/R injury were performed at two
weeks after orthotopic liver tumor implantation. YQ23 (0.2 g/kg) was administered at 1 hour before ischemia and
immediately after reperfusion. Blood samples were collected at day 0, 1, 7, 14, 21 and 28 for detection of circulating
endothelial progenitor cells (EPCs) and regulatory T cells (Tregs).
Results: Our results showed that YQ23 treatment effectively inhibited intrahepatic and lung metastases together
with less tumor angiogenesis at 4 weeks after major hepatectomy and partial hepatic I/R injury. The levels of
circulating EPCs and Tregs were significantly decreased in YQ23 treatment group. Furthermore, YQ23 treatment also
increased liver tissue oxygenation during hepatic I/R injury. Up-regulation of HO1 and down-regulation of CXCR3,
TNF-α and IL6 were detected after YQ23 treatment.
Conclusions: YQ23 treatment suppressed liver tumor metastasis after major hepatectomy and partial hepatic I/R
injury in a rat liver tumor model through increasing liver oxygen and reducing the populations of circulating EPCs
and Tregs.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies in the world, claiming 600,000
victims each year [1]. Although remarkable advances in
diagnostic and non-surgical therapeutic techniques have
been made in the recent years, surgical therapies such as
liver resection and liver transplantation are still the first-
line treatments for HCC patients. However, the high
incidence of tumor metastasis after liver surgery remains* Correspondence: kwanman@hkucc.hku.hk
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unless otherwise stated.a major problem [2,3]. Therefore, it is very important to
develop novel therapies to reduce liver tumor metastasis
after liver surgery.
Surgical stress injury such as liver ischemia and hyp-
oxia are inevitable consequence during liver surgery. Ac-
cumulating evidence suggested that tissue ischemia and
hypoxia can rapidly increase the number of circulating
EPCs and Tregs [4-6]. These events are also associated
with elevated levels of hypoxia inducible factor-1α (HIF-
1α) responsive chemokines and inflammatory cytokines/
chemokines that stimulate the release and recruitment
of EPCs and Trges from the bone marrow [4,6-10]. EPCs
play important roles in tumor vasculogenesis and tumorhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. BMC Cancer 2014, 14:293 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/293growth at early phase by providing structural support to
nascent vessels and the release of pro-angiogenic cytokines
[11,12]. Furthermore, EPCs have major roles in control an-
giogenic switch of metastasis transition from micrometas-
tases to macrometastases [13]. CD4+CD25+Foxp3+ Tregs
play a critical role in the control of antitumor immune re-
sponses [14,15]. It has been found that increased numbers
of Tregs are detected in peripheral blood of cancer pa-
tients and accumulate in tumor regions [16-18].
YQ product is the stabilized non-polymeric cross-linked
tetrameric hemoglobin (65 kDa) with undetectable/low
level of dimeric hemoglobin (32 kDa), phospholipid, DNA
impurities and protein impurities. Recent research showed
that the similar product OC89 can effectively increase the
ability to carry oxygen and enhance cisplatin-based TACE
[19]. In this study, we aimed to investigate whether the
treatment of YQ23 can suppress liver tumor metastasis
after major hepatectomy and partial hepatic I/R injury by
increasing liver oxygen and then reducing circulating
EPCs and Tregs levels in an orthotopic rat liver tumor
model. The significance of this study will hopefully pro-
vide a novel means to suppress liver tumor metastasis
after liver surgery for HCC patients.
Methods
Animal model
Buffalo rats (Male, 8-10weeks, 350-400 g) were obtained
from lab animal unit, The University of Hong Kong. Before
operation, rats were anesthesia with pentobarbitone (40 mg/
kg, ip) and after operation buprenorphine (0.05-0.1 mg/kg/
12 hours) were given for attenuating the analgesics.
Rats were housed in a standard animal laboratory with
free activity and access to water and food. They were
kept under constant environment conditions with a
12-hour light–dark cycle. All operations were performed
under clean conditions. The study had been licensed
according to Animal Ordinance Chapter 340 by the
Department of Health, Hong Kong Special Administrative
Region (ref.: (12–222) in DH/HA&P/8/2/3 Pt. 39). Hepato-
cellular carcinoma cell line McA-RH7777 (Purchased from
the American Type Culture Collection, Number CRL1601,
ATCC, Manassas, VA, USA) were used to establish the
orthotopic liver cancer model in Buffalo rat [20]. Two
weeks after orthotopic liver tumor implantation, The
branch of hepatic artery and portal vein to right and
triangle lobes are clamped for 30 minutes (ischemia
duration) following by reperfusion (release of the clamp).
Major hepatectomy of tumor-bearing lobe (left lobe) is
performed during the ischemia duration.
Treatment regimen and sample collection
YQ23 products were obtained from New B Innovation
Limited. YQ23 product is the stabilized non-polymeric
cross-linked tetrameric hemoglobin (65 kDa) withundetectable/low level of dimeric hemoglobin (32 kDa),
phospholipid, DNA impurities and protein impurities.
The concentration of YQ product is 10 g/dL and its pH
range is 7.2-7.8. The osmolality and viscosity (at 37°C)
are >250 mOsm/kg and 0.9 centipoise respectively. The
p50 value is ~ 40 mmHg. The information for YQ product
is shown in patent no. US7,932,356 B1, US 8,048,856 B1
and PCT/US12/46130. YQ23 (0.2 g/kg, treatment group)
or the same volume of ringer’s acetate buffer (control
group) were administrated intravenously at 1 hour before
ischemia. An additional 0.2 g/kg YQ23 or the same vol-
ume of ringer’s acetate buffer was injected through hepatic
portal vein immediately after reperfusion. Blood samples
were taken at days 0, 1, 7, 14, 21 and 28 from tail vein for
detecting the populations of circulating EPCs and Tregs.
And then Buffalo rats were sacrificed at 4 weeks after
major hepatectomy and partial hepatic I/R injury to
monitor liver tumor metastasis. Liver and lung were
sampled for further investigation.
Hematoxylin and Eosin (H & E) and Immunohistochemical
(IHC) Staining
The histological changes were detected by H& E staining
and the expression of CD34 (Santa Cruz Biotechnology)
were detected by immunohistochemical staining. The
details of H & E and IHC staining were described in our
previous paper [20]. In brief, after rehydrated in water,
the paraffin sections placed in citric buffer (pH 6.0) and
treated in a microwave. Afterwards, the sections under-
went blocking with 10% FBS and then primary anti-
bodies were applied (incubated at 4°C overnight). Then
the sections underwent blocking with 3% peroxidase for
30 min and secondary antibodies from Dako EnVision
System (DakoCytomation) were applied. Signals were
developed with 3,3’-diaminobenzidine substrate solution
(DakoCytomation).
Determination of microvessel density and tumor load
analyses
Microvessel density (MVD) of intrahepatic metastatic
tumor sections was evaluated [21]. The mean number of
tumor nodules in the lungs and liver, as well as tumor
volume of intrahepatic metastatic nodules (L ×W2/2)
was calculated and expressed as average [22].
Detection of circulating EPCs and Tregs by flow
cytometry
The number of circulating EPCs and Tregs were de-
tected by flow cytometry. The details of flow cytometry
were described in our previous paper [20]. For analysis
of EPC cell surface molecules, cells were stained with
the following antibodies: unconjugated rabbit anti-CD133
(Abcam, Cambridge, UK), PE-conjugated anti-CD34 (Santa
Cruz Biotech, Santa Cruz, CA), VEGFR2+ (BD Pharmingen,
Table 1 Comparison of liver tumor metastasis after major








Metastasis ratio 9/13(69.2%) 4/11(36.4%) 0.107
Tumor size(cm3) 0.201 ± 0.058 0.059 ± 0.029 0.045*
Number(tumor nodules)/rat 3.539 ± 1.767 0.636 ± 0.310 0.151
Lung metastasis
Metastasis ratio 7/13(53.8%) 4/11(36.4%) 0.392
Number(tumor nodules)/rat 2.154 ± 1.143 1.00 ± 0.539 0.399
Note: average ± SEM *p < 0.05.
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antibody (Abcam, Cambridge, UK). For analysis of Treg
cells, cells were stained with PE-Cy5-conjugated anti
CD4 (eBioscience, San Diego, CA) and PE-conjugated
anti CD25 (BD Pharmingen, San Diego, CA), and then
permeabilized with fixation/permeabiliation working so-
lution and incubated with FITC-conjugated anti-Foxp3
(eBioscience, San Diego, CA).
Determination of liver oxygenation
Liver tissue oxygenation (Liver pO2) was directly moni-
tored by the OxyLab® in vivo monitoring system (OxfordFigure 1 YQ23 suppressed liver tumor intrahepatic and lung metasta
sacrificed at 4 weeks after major hepatectomy and hepatic I/R injury to mo
detected in specimen at four weeks after major hepatectomy and partial I/
tumors at four weeks after hepatectomy and partial I/R injury with and witOptronix, UK) during the ischemia and reperfusion pro-
cedures in another group of Buffalo rats. Briefly, a large-
area-surface (LAS) oxygen sensor (Oxford Optronix, UK)
was placed between the right hepatic lobe and triangle
lobe of the rat livers. The branch of hepatic artery and
portal vein to right and triangle lobes were clamped for
30 minutes following by reperfusion. YQ23 (0.2 g/kg,
treatment group) or ringer’s acetate buffer (control group)
were administered intravenously at 1 hour before ische-
mia. An additional 0.2 g/kg YQ23 or ringer’s acetate buffer
was injected through hepatic portal vein immediately after
reperfusion. Liver oxygen tension was continuously mea-
sured during hepatic ischemia reperfusion injury: 1) base-
line; 2) after infusion of YQ23 or ringer’s acetate buffer;
3) during ischemia; and 4) after onset of reperfusion.
Assessment of hepatic gene expression profiles
In order to investigate the effect of YQ23 on expressions
of cytokines/chemokines, a new group of Buffalo rats
were included for major hepatecotmy and partial hepatic
I/R injury. YQ23 or ringer’s acetate buffer were adminis-
tered at 1 hour before ischemia and immediately after
reperfusion. Liver samples were collected at 6 hours
after reperfusion and gene expressions were detected
by reverse transcription-polymerase chain reaction (RT-
PCR) [20]. Gene expression levels were expressed as thesis after major hepatectomy and partial I/R injury. Buffalo rats were
nitor tumor metastasis. (A) Intrahepatic and lung metastasis were
R injury. (B) Histological features of intrahepatic and lung metastasis
hout YQ23 treatment. (T = tumor; NT = Non-tumor).
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primers were listed as follows: CXCR3: Left AGCACA
GACACCTTCCTGCT, Right CAGAGACCAGAGCCG
AAAAC; TNF-α: Left GTCTGTGCCTCAGCCTCTTC,
Right CCCATTTGGGAACTTCTCCT. IL6: Left GCCC
TTCAGGAACAGCTATG, Right GTCTCCTCTCCGGA
CTTGTG; HO1: Left GAAGAAGATTGCGCAGAAGG,
Right TTCATGCGAGCACGATAGAG.Statistics and data analyses
Continuous variables were expressed as average. T-TEST
was applied to delineate the difference between the treat-
ment and control groups. Chi-Square (χ2) test was used to
compare incidence of intrahepatic and lung metastasis
after major hepatectomy and partial hepatic I/R injury.
p < 0.05 was considered statistically significant. Calculations
were performed by using the SPSS computer software
version 16 (SPSS, Chicago, IL).Figure 2 Comparison of tumor angiogenesis in intrahepatic
metastatic tumor. CD34 positive cells in intrahepatic metastatic
tumor nodules were detected by IHC staining. (A) The expression
of CD34 positive cells in intrahepatic metastatic tumor nodules.
(B) Comparison of MVD in metastatic tumor nodules between YQ23
group and control group. (**p < 0.01; Treatment group N = 4; Control
group N = 6).Results
YQ23 suppressed liver tumor metastasis after major
hepatectomy and partial hepatic I/R injury
In order to investigate the effect of YQ23 on the metas-
tasis of liver tumor after liver surgery, we established a
rat orthotopic liver tumor model with local and distant
metastatic potentials. The results showed that, after YQ23
treatment, the incidence of intrahepatic metastasis re-
duced from 69.2% (9 of 13) to 36.4% (4 of 11). Similarly,
YQ23 treatment also decreased the lung metastasis from
53.8% (7 of 13) to 36.4% (4 of 11) (Table 1). More import-
antly, the tumor volume of intrahepatic metastatic nod-
ules was significantly decreased in YQ23 treatment groupFigure 3 Comparison of circulating EPCs and Tregs. The
populations of circulating EPCs and Tregs were detected by flow
cytometry at day 0, 1, 7, 14, 21, 28 after major hepatectomy and
I/R injury. (A) The level of circulating EPCs was compared between
YQ23 treatment and control groups. (B) The number of circulating
Tregs was detected in YQ23 treatment and control groups.
(**p < 0.01; N = 3/group).
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Furthermore, the number of metastatic tumor nodules in
liver and lung were also reduced after YQ23 treatment
(intrahepatic metastasis: 3.5 vs 0.6, p = 0.15; lung metastasis:
2.2 vs 1.0, p = 0.4) (Table 1). Intrahepatic and lung
metastasis were further confirmed by histology exam-
ination (Figure 1B).YQ23 decreased the MVD in intrahepatic metastatic
tumor nodules
At four weeks after major hepatectomy and partial
hepatic I/R injury, IHC staining revealed that strong
expression of CD34 in intrahepatic metastatic tumor
nodules were detected in the control group. On the
contrary, only weak CD34 expression was found in the
YQ23 treatment group (Figure 2A). Furthermore, YQ23
treatment significantly reduced MVD in intrahepatic meta-
static tumor nodules (36.4 vs 72.96; p < 0.01) (Figure 2B).YQ23 significantly reduced circulating EPCs
EPCs play important roles in tumor vasculogenesis and
tumor growth at early phase by providing structural sup-
port to nascent vessels and the release of pro-angiogenic
cytokines. In order to explore the underlying mechanism
of YQ23 on suppressing liver tumor metastasis, we de-
tected the levels of the circulating EPCs at different time
points after major hepatectomy and I/R injury. The level
of circulating EPCs was decreased at day 1 after the
major hepatectomy and partial I/R injury in both control
and treatment group. After that, compared to control
group, the level of circulating EPCs was significantly re-
duced after YQ23 treatment at day 7 and day 28 (day7:
44.6 vs 190.9/105 PBMC cells, p = 0.001; day28: 155.0 vs
496.6/105 PBMC cells, p = 0.005) (Figure 3A). At day
14 and day 21, the treatment of YQ23 also effectively
decreased the circulating EPCs levels (day14: 167.4 vs
278.8/105 PBMC cells, p = 0.06; day21: 296.1 vs 506.2/105
PBMC cells, p = 0.13) (Figure 3A).Figure 4 YQ23 increased liver pO2 during hepatic I/R
procedure. Liver pO2 level was directly monitored by the OxyLab®
in vivo monitoring system during the ischemia and reperfusion
procedures. (A) Representative liver pO2 curves during ischemia
reperfusion procedures were presented. (B) Average liver pO2 level
was showed at different time points during ischemia reperfusion
procedures. (*p < 0.05; Treatment group N = 6; Control group N = 7).YQ23 significantly reduced circulating Tregs
Tregs play a critical role in antitumor immune responses.
They can suppress the immune responses against tumors
and thereby promote tumor growth. The results showed
that the number of circulating Tregs was reduced at day 1
after the major hepatectomy and partial I/R injury in both
groups. The level of circulating Tregs was significantly
decreased by YQ23 treatment from day 7 to day 28 (day7:
134.6 vs 192.9/105 PBMC cells, p = 0.003; day14: 68.8 vs
164.7/105 PBMC cells, p = 0.002; day21: 153.2 vs 322.2/105
PBMC cells, p = 0.004; day28: 165.9 vs 419.4/105 PBMC
cells, p < 0.001) (Figure 3B).Administration of YQ23 increased liver pO2 during
ischemia and reperfusion process
Accumulating evidence indicated that tissue ischemia
and hypoxia, through elevated levels of HIF-1α respon-
sive chemokines such as SDF-1α and VEGF, stimulate
the release and recruitment of EPCs and Tregs from the
bone marrow. In order to explore the underlying mech-
anism of YQ23 on suppression of circulating EPCs and
Tregs, pO2 levels in liver tissue during hepatic IR injury
were compared between control and treatment group.
Representative continuous measurement of liver pO2 in
rats following intravenous administration of YQ23 and
control during the ischemia reperfusion procedures was
presented in Figure 4A. At baseline, the average liver pO2
did not show significant difference between the treatment
and control group (15.7 vs 15.4 mmHg; p = 0.93). One
hour after YQ23 or buffer injection, YQ23 treatment ef-
fectively increased liver pO2 level (22.3 vs 13.7 mmHg,
p = 0.19) although the values did not reach a statistical
significant level (Figure 4B). During ischemia, although
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group, YQ23 treatment resulted in a significantly higher
pO2 (11.2 mmHg) when compared with control group
(0.1 mmHg, p = 0.045). After reperfusion, the pO2 level
in liver was also found to be elevated in YQ23 treat-
ment group (18.7 vs 6.5, p = 0.036) (Figure 4B).
YQ23 treatment increased HO1 expression and down-
regulated the expressions of CXCR3, TNF-α and IL6
In order to explore the underlying mechanism of YQ23
on suppression of circulating EPCs and Tregs, the mRNA
expression levels of CXCR3, TNF-α, IL6 and HO1 in liver
tissue were compared between control group and treat-
ment group. YQ23 significantly increased HO1 expression
and down-regulated expressions of CXCR3, TNF-α and
IL6 in liver tissue at 6 hours after major hepatectomy and
hepatic I/R injury compared to control group (Figure 5).
Discussion and conclusions
In the present study, the effect of YQ23 on inhibition of
liver tumor metastasis after liver resection and I/R injury
was first shown in an orthotopic rat liver tumor model
with local and distant metastatic potentials. Although
the incidence of tumor metastasis in both intrahepatic
and lung after YQ23 treatment didn’t reach a statistical
difference level, the incidence was reduced by approxi-
mately 50% (From 69.2% to 36.4% in liver; from 53.8% to
36.4% in lung). In addition to reducing the incidence of
intraheptic and lung metastasis, YQ23 also decreased
the number and size of metastatic tumor nodules at four
weeks after major hepatectomy and hepatic I/R injury.
These results suggest that the YQ23 treatment mayFigure 5 YQ23 increased HO1 expression and down-regulated the ex
detected by real time RT-PCR at 6 hours after major hepatectomy and hepprovide a novel means to prevent liver cancer metastasis
after liver surgery for HCC patients.
Liver ischemia and hypoxia are inevitable consequence
due to operation or clamp during liver surgery. It can lead
to a set of liver damage and change in micro environment.
Accumulating evidence indicated that tissue ischemia and
hypoxia induced the production of HIF-1α responsive che-
mokines and inflammatory cytokines/chemokines [4-6].
They play important roles in stimulating the release and
recruitment of EPCs and Trges from the bone marrow
[6-10]. Recently, we have also demonstrated that post-
transplant endothelial progenitor cell mobilization via
CXCL10/CXCR3 signaling promoted liver tumor growth
[10]. In this study, our results showed that YQ23 treat-
ment decreased CXCR3 expression after I/R injury. The
reduction of circulating EPCs and Tregs levels may due to
the down-regualation of CXCR3 after I/R injury. Further-
more, YQ23 treatment also decreased the expressions of
TNF-α and IL6, which play important roles in the patho-
genesis of hepatic I/R injury. On the other hand, YQ23
treatment increased liver pO2 level during operation and
HO1 expression after hepatic I/R injury. A wealth of data
has proven that HO1 and its metabolites protect liver
from hepatic I/R injury through modulating inflammatory
responses and anti-oxidant/oxidant homeostasis [23].
Bone marrow derived EPCs have the capacity to mi-
grate to the peripheral circulation and differentiate into
mature endothelial cells [24,25]. Several studies have
demonstrated that EPCs play important roles in the
development of tumor vasculature. They contribute to
early-stage tumor vascularization, promote tumor growth
and control angiogenic switch of metastasis transitionpressions of CXCR3, TNF-α and IL6. Hepatic gene expressions were
atic I/R injury. *P < 0.05; N = 4/group.
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or integaration can result in significant angiogenesis inhib-
ition and impaired tumor growth and metastasis [26,27].
In this study, our results showed that YQ23 reduced the
number of circulating EPCs at different time point after
liver tumor resection and I/R injury. The phenomenon
was consistent with the decrease of MVD in metastatic
tumor nodules.
In addition to the reduction of circulating EPCs levels,
the present study also demonstrated that YQ23 de-
creased the levels of circulating Tregs after liver resec-
tion and hepatectomy. Recent studies have shown that
CD4+CD25+Foxp3+ Tregs, which are physiologically en-
gaged in the maintenance of immunological self-tolerance
and immune homeostasis, play a critical role in the con-
trol of antitumor immune responses [14,15]. It has been
found that increased numbers of Tregs are detected in
peripheral blood of cancer patients and accumulate in
tumor regions [16-18]. Furthermore, deletion or inhibition
of Tregs effectively enhanced antitumor responses and
inhibited tumor growth [28,29]. Therefore, the effect
of YQ23 on inhibition of liver tumor metastasis was
probably due to the decrease of circulating EPCs and
Tregs levels. Targeting circulating EPCs and Tregs by
YQ23 treatment may effectively decrease tumor metas-
tasis after liver surgery.
In conclusion, YQ23 suppressed liver tumor metastasis
after major hepatectomy and partial hepatic I/R injury
through increasing liver oxygenation and reducing the
number of circulating EPCs and Tregs, suggesting that
it may be a promising candidate for potential adjuvant
therapies for treating liver cancer metastasis after liver
surgery for HCC patients.
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